Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.

导出 OA

翻译打印收藏纠错

作者： Agnès,Linglart ^[1] ; Erik A,Imel ^[2] ; Michael P,Whyte ^[3] ; Anthony A,Portale ^[4] ; Wolfgang,Högler ^[5] ; Annemieke M,Boot ^[6] ; Raja,Padidela ^[7] ; William,Van't Hoff ^[8] ; Gary S,Gottesman ^[9] ; Angel,Chen ^[10] ; Alison,Skrinar ^[11] ; Mary,Scott Roberts ^[12] ; Thomas O,Carpenter ^[13]

作者单位： AP-HP, Endocrinology and Diabetes for Children, Reference Center for Rare Disorders of the Calcium and Phosphate Metabolism, and Filière OSCAR, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France. ^[1] Paris-Saclay University, INSERM 1189, Le Kremlin-Bicêtre, France. ^[2] Indiana University School of Medicine, Indianapolis, IN, USA. ^[3] Shriners Hospitals for Children - St. Louis, MO, USA. ^[4] Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA. ^[5] University of California, San Francisco, CA, USA. ^[6] Johannes Kepler University Linz, Linz, Austria. ^[7] University of Birmingham, Birmingham, UK. ^[8] University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. ^[9] Royal Manchester Children's Hospital and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. ^[10] Great Ormond Street Hospital, London, UK. ^[11] Shriners Hospitals for Children - St. Louis, St Louis, MO, USA. ^[12] Ultragenyx Pharmaceutical Inc., Novato, CA, USA. ^[13] Yale University School of Medicine, New Haven, CT, USA. ^[14]

关键词 calcitriol growth hypophosphatemia osteomalacia phosphate rickets